Cancer Watch
@Cancer_watch
Followers
73
Following
3K
Media
2
Statuses
911
Cancer Watch - Keeping up to date with the latest cancer news and developments throughout the world. Beating cancer one tweet at a time.........................
Joined October 2019
RT @JAMAOnc: Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI)….
0
42
0
RT @DrMarkLythgoe: Simple things work best in #clinical #trial recruitment - single page recruitment letter………….though no preference in dif….
0
2
0
RT @LGHemkens: Excellent meta-research: A trial within a large trial shows that consent form length impacts recruitment. Please consider to….
0
10
0
New important @FDAOncology approval for #NSCLC in oncology - #accelerated #approval so caution needed with data.
New @US_FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05.▫️ORR: 45%.▫️DoR: 6.5 mo.⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk. @OncoAlert #lcsm
0
0
2
RT @BMJOncology: This study builds on recent work that calls for increased female representation in oncology leadership and authorship. htt….
0
2
0
RT @SuyogCancer: Practicing Oncologist and fellows from across the world 🌎 if u want join this academic what's up group, do message me 🙂.….
0
4
0
RT @diegoadiazg: 📊 Are we overestimating success in ph3 oncology trials? . 📉 Only 6% of ph3 oncology RCTs show improvement in both OS and Q….
0
40
0
RT @JAMAOnc: Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based….
0
20
0
RT @BMJOncology: People with intellectual disability have a unique cancer profile, shaped in part by the heterogeneity of the underlying ca….
0
1
0
RT @TheLancet: 🗨️ “Vaccines have done more to improve public health than any other medical intervention.”. A new Viewpoint focuses on cance….
0
458
0
An important spotlight on an issue many affected by #lungcancer know too well. As rates rise among younger women - incl. many who have never smoked - the gaps in early diagnosis & access are becoming even more apparent. Thank you @DrNarjust for your expertise & leadership, & to.
0
0
1
RT @Michelle_CRUK: Delighted to share this news on the appointment of Professor Samra Turajlic as the Director of the @CRUK_MI. Samra is a….
0
1
0
RT @DrMarkLythgoe: Excellent article 'The Catch in Catching Cancer Early' from @DrSidMukherjee in the @NewYorker discussing the promise of….
0
7
0
RT @ADesaiMD: 🧵New commentary published in @JAMANetworkOpen on real-world treatment patterns after platinum + IO in advanced #NSCLC, work b….
0
8
0
New @US_FDA new policy, less resources, slower approvals and missed PDUFAs - is this something we are going to see in #oncology? . @VPrasadMDMPH @MartyMakary @FDAOncology.
$KALV KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints.
0
0
1
#Ivermectin in #cancer treatment and prevention continues to dominate many #oncology consults - Trials with our best drugs have shown little or no benefit #ASCO25 .
1
1
2
New #trojanhorse treatment available for #UK patients with #myeloma - #belantamabmafodotin. @MyelomaUK @CR_UK @bloodcancer_uk @myeloma @myelomabeacon @MyelomaEurope @MYELOMA360 @pash22 @LMRUK_org .
1
0
1
RT @ASCO: We are thrilled to welcome our 2025 summer intern cohort joining ASCO for the next 10 weeks! We're excited to have them supportin….
0
8
0
RT @TheLancetOncol: 📍Our Editor-in-Chief, David Collingridge, is currently at a special event in Amman, Jordan, to launch the Series on Can….
0
7
0
Another new @US_FDA oncology drug approval - mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive #bladdercancer . @WorldBladderCan @BladderCancerUS @IBCG_BladderCA @ABLCS .
0
2
5